Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Urcosimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OKYO Abstract Chosen For Premier Global Ophthalmology Conference
    OKYO Abstract Chosen For Premier Global Ophthalmology Conference

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242801/0/en/OKYO-Abstract-Selected-for-Presentation-at-Premier-Global-Ophthalmology-Congress.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    OKYO Pharma Presents Urcosimod Phase 2 Data at ASCRS Meeting
    OKYO Pharma Presents Urcosimod Phase 2 Data at ASCRS Meeting

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229643/0/en/OKYO-Pharma-Announces-Acceptance-of-Urcosimod-Phase-2-Study-Results-for-Presentation-at-Prestigious-ASCRS-Annual-Meeting.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    OKYO Pharma Announces Successful Type C Meeting With The FDA
    OKYO Pharma Announces Successful Type C Meeting With The FDA

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3227523/0/en/OKYO-Pharma-Announces-Successful-Type-C-Meeting-with-the-FDA.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    FDA Approves Urcosimod 0.05% to Treat Neuropathic Corneal Pain
    FDA Approves Urcosimod 0.05% to Treat Neuropathic Corneal Pain

    23 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/23/3224608/0/en/FDA-Approves-Compassionate-Use-of-Urcosimod-0-05-for-the-Treatment-of-Neuropathic-Corneal-Pain.html

    GLOBENEWSWIRE
    23 Jan 2026
    Share Share
    OKYO Pharma Announces Chairman And Founder Acquires Shares
    OKYO Pharma Announces Chairman And Founder Acquires Shares

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205428/0/en/OKYO-Pharma-Announces-Chairman-and-Founder-Acquires-Shares.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    Okoyo Pharma Reports Positive Corneal Nerve Results
    Okoyo Pharma Reports Positive Corneal Nerve Results

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203917/0/en/OKYO-Pharma-Announces-New-Data-Showing-Favorable-Corneal-Nerve-Outcomes-in-Phase-2-Study-for-Neuropathic-Corneal-Pain.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.